For research use only. Not for therapeutic Use.
Phenprocoumon is a long-acting oral anticoagulant drug, a derivative of coumarin. It is a vitamin K antagonist that inhibits coagulation by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders.
| Catalog Number | R040265 |
| CAS Number | 435-97-2 |
| Synonyms | 4-Hydroxy-3-(1-phenylpropyl)-2H-1-benzopyran-2-one; 3-(α-Ethylbenzyl)-4-hydroxy-coumarin; (±)-Phenprocoumon; 3-(1-Phenylpropyl)-4-hydroxycoumarin; 3-(α-Ethylbenzyl)-4-hydroxycoumarin; 3-(α-Phenylpropyl)-4-hydroxycoumarin; 4-Hydroxy-2-oxo-3-(1-phenylp |
| Molecular Formula | C18H16O3 |
| Purity | ≥95% |
| Storage | -20°C |
| IUPAC Name | 4-hydroxy-3-(1-phenylpropyl)chromen-2-one |
| InChI | InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3 |
| InChIKey | DQDAYGNAKTZFIW-UHFFFAOYSA-N |
| SMILES | CCC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O |
| Reference | </br>1:Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon. Sauter TC, Hegazy K, Hautz WE, Krummrey G, Riklin ME, Nagler M, Borner U, Exadaktylos AK.Clin Otolaryngol. 2017 May 16. doi: 10.1111/coa.12904. [Epub ahead of print] PMID: 28510336 </br>2:Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Hohnloser SH, Basic E, Nabauer M.Clin Res Cardiol. 2017 Mar 14. doi: 10.1007/s00392-017-1098-x. [Epub ahead of print] PMID: 28293797 </br>3:Pregnancy outcome of first trimester exposure to the vitamin K antagonist phenprocoumon depends on duration of treatment. Hüttel E, Padberg S, Meister R, Beck E, Schaefer C.Thromb Haemost. 2017 May 3;117(5):870-879. doi: 10.1160/TH16-11-0838. Epub 2017 Feb 23. PMID: 28229160 </br>4:[Primary enucleation in an avulsion injury : A high-risk procedure under phenprocoumon]. Pettenkofer M, Lohmann C, Klopfer M.Ophthalmologe. 2017 Jan 31. doi: 10.1007/s00347-017-0445-7. [Epub ahead of print] German. PMID: 28144737 </br>5:Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT group..J Thromb Haemost. 2017 Mar;15(3):454-464. doi: 10.1111/jth.13601. Epub 2017 Feb 17. PMID: 27992949 </br>6:Massive intoxication with rivaroxaban, phenprocoumon, and diclofenac: A case report. Pfeiffer H, Herbst L, Schwarze B, Eckstein R, Weisbach V.Medicine (Baltimore). 2016 Nov;95(44):e5343. PMID: 27858919 Free Article</br>7:Percutaneous Dilatation Tracheostomy in Patients with Left Ventricular Assist Device and Established Phenprocoumon Therapy. Schaefer A, Schneeberger Y, Reichart D, Bernhardt AM, Kubik M, Barten MJ, Wagner FM, Kluge S, Reichenspurner H, Philipp SA.ASAIO J. 2016 Nov/Dec;62(6):715-718. PMID: 27556147 </br>8:Genetic variations of phenprocoumon metabolism in patients with ventricular assist devices. Brehm K, Krumnau O, Heilmann C, Beyersdorf F.Eur J Cardiothorac Surg. 2016 Aug;50(2):275-80. doi: 10.1093/ejcts/ezw060. Epub 2016 Mar 16. PMID: 26984978 </br>9:[Mechanic valve prosthesis and pregnancy: Is Phenprocoumon replaceable?]. Klee K, Gawaz M, Meyer-Zürn CS.Dtsch Med Wochenschr. 2016 Mar;141(5):346. doi: 10.1055/s-0041-104684. Epub 2016 Mar 3. German. PMID: 26939105 </br>10:Different Heparin Contents in Prothrombin Complex Concentrates May Impair Blood Clotting in Outpatients With Ventricular Assist Devices Receiving Phenprocoumon. Felli A, Zeidler P, Jilma B, Opfermann P, Holaubek C, Zimpfer D, Wadowski PP, Steinlechner B.J Cardiothorac Vasc Anesth. 2016 Jan;30(1):96-101. doi: 10.1053/j.jvca.2015.08.012. Epub 2015 Aug 14. PMID: 26613641 |
